Free shipping on all orders over $ 500

BMS-986158

Cat. No. M13819
BMS-986158 Structure
Size Price Availability Quantity
5mg USD 325  USD325 In stock
10mg USD 600  USD600 In stock
Free Delivery on orders over USD 500 Bulk Inquiry?

Quality Control & Documentation
Biological Activity

BMS-986158 is a potent BET inhibitor with IC50s of 6.6 and 5 nM in NCI-H211 small cell lung cancer (SCLC) cells and MDA-MB231 triple negative breast cancer (TNBC) cells, respectively.

Chemical Information
Molecular Weight 495.62
CAS Number 1800340-40-2
Solubility (25°C) DMSO 50 mg/mL
Storage Powder          -20°C   3 years ;  4°C   2 years
In solvent       -80°C   6 months ;  -20°C   1 month
Conversion of different model animals based on BSA (PMID: 27057123)
Species Mouse Rat Rabbit Guinea pig Hamster Dog
Weight (kg) 0.02 0.15 1.8 0.4 0.08 10
Body Surface Area (m2) 0.007 0.025 0.15 0.05 0.02 0.5
Km factor 3 6 12 8 5 20
Animal A (mg/kg) = Animal B (mg/kg) multiplied by  Animal B Km
Animal A Km

For example, to modify the dose of Compound A used for a mouse (20 mg/kg) to a dose based on the BSA for a rat, multiply 20 mg/kg by the Km factor for a mouse and then divide by the Km factor for a rat. This calculation results in a rat equivalent dose for Compound A of 10 mg/kg.

References

[1] Xu-Sheng Huang, et al. Pharmaceuticals (Basel). Bromodomain and Extra-Terminal Inhibitor BMS-986158 Reverses Latent HIV-1 Infection In Vitro and Ex Vivo by Increasing CDK9 Phosphorylation and Recruitment

[2] Ashvinikumar V Gavai, et al. J Med Chem. Discovery and Preclinical Pharmacology of an Oral Bromodomain and Extra-Terminal (BET) Inhibitor Using Scaffold-Hopping and Structure-Guided Drug Design

[3] Andrew Dj Pearson, et al. Eur J Cancer. Bromodomain and extra-terminal inhibitors-A consensus prioritisation after the Paediatric Strategy Forum for medicinal product development of epigenetic modifiers in children-ACCELERATE

[4] Yanli Sun, et al. Front Pharmacol. Safety and Efficacy of Bromodomain and Extra-Terminal Inhibitors for the Treatment of Hematological Malignancies and Solid Tumors: A Systematic Study of Clinical Trials

[5] Mingzhu Yin, et al. Nat Commun. Potent BRD4 inhibitor suppresses cancer cell-macrophage interaction

Related Epigenetic Reader Domain Products
Phoenixin-20

Phoenixin-20 (PNX-20) is a bioactive peptide with hormone-like actions in vertebrates, and can stimulates hypothalamo-pituitary-gonadal hormones and regulate reproductive processes in mammals.

Menin-MLL inhibitor 31

Menin-MLL inhibitor 31 is a potent inhibitor of the menin MLL interaction with an IC50 value of 4.6 nM.

OPN-2853

OPN-2853 is a bromodomain protein-4 (BRD4) inhibitor that can be used in studies related to hematologic and lymphatic disorders.

HDAC/JAK/BRD4-IN-1

HDAC/JAK/BRD4-IN-1 is a potent HDAC/JAK/BRD4 triple inhibitor.

VYN-201

VYN-201 is a novel pan-BET inhibitor for studies related to idiopathic pulmonary fibrosis.

  Catalog
Abmole Inhibitor Catalog




Keywords: BMS-986158 supplier, Epigenetic Reader Domain, inhibitors, activators


Products are for research use only. Not for human use. We do not sell to patients.
© Copyright 2010-2023 AbMole BioScience. All Rights Reserved.